New Lung-on-a-Chip Mimics TB Infection in Real Time

New Lung-on-a-Chip Mimics TB Infection in Real Time

Scientists have made a human lung-on-a-chip that mimics the tiny air sacs in the lungs, called alveoli. You could say it’s like a mini-lung in a lab dish. It might help researchers understand how TB infects the lungs and how treatments could work for different people.

The study, published in Science Advances, comes from the Francis Crick Institute and biotech company AlveoliX. They used stem cells from a single donor to make the model. That’s important because previous models mixed different cell types and often didn’t behave like a real lung.

Why It’s Important

Alveoli are key for breathing and act as a barrier against viruses and bacteria. Studying them has been hard because animal models and mixed-cell systems don’t replicate human lung function well. Max Gutierrez, PhD, from the Crick, said organ-on-chip models are “becoming more important to recreate human systems while avoiding differences between humans and animals.”

How the Chip Works

Researchers grew alveolar epithelial cells and blood vessel cells on opposite sides of a thin membrane. The device stretches the membrane to simulate breathing. Because all cells come from the same donor, it can mimic how an individual’s lung might respond to infection.

When infected with TB, clusters of dead macrophages appeared. After five days, the barriers broke down, showing early lung damage. Jakson Luk, PhD, said TB is slow to show symptoms, and the chip gives a “holistic picture of how different lung cells respond early on.”

What’s Next

The team wants to use the model for other infections, lung cancer, and testing personalized treatments. They also plan to add more cell types to make it even more realistic. For now, it’s a promising step toward studying lung disease in a human-relevant way.

AktieGo

More Market Insights
on YouTube

Watch our latest market briefings, CEO interviews and stock deep dives covering the companies and sectors we follow.

The Uranium Comeback: Why Nuclear Is Back
The Uranium Comeback: Why Nuclear Is Back
Executive Insights with Kevin Hull, Emergent Waste Solutions CEO
Executive Insights with Kevin Hull, Emergent Waste Solutions CEO
The Tungsten Supply War
The Tungsten Supply War: Why One Company Stock Rose 2,400% and Others May Follow
Market Briefings
3× per week
Stock Deep Dives
In-depth analysis
CEO Interviews
Exclusive insights
Emerging Sectors
Mining · Tech · Energy · Biotech
The AktieGo Brief

The market moves fast.
Our briefing keeps up.

Curated updates on stock picks, company spotlights, and in-depth market analysis across mining, biotech, energy, crypto, and tech — delivered straight to your inbox. Join thousands of investors who start their morning with the AktieGo Brief.

Name


BRIEF